Analysts think AVTX stock price could increase by 320%
Mar 14, 2025, 11:25 AM
-31.22%
What does AVTX do
Avalo Therapeutics, a clinical-stage biotechnology company headquartered in Rockville, Maryland, focuses on immune dysregulation therapies, with key assets including AVTX-009, quisovalimab, and AVTX-008. The company went public on November 13, 2015, and employs 19 people.
6 analysts think AVTX stock price will increase by 320.25%. The current median analyst target is $30.09 compared to a current stock price of $7.16. The lowest analysts target is $18.18 and the highest analyst target is $42.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
